JERUSALEM, January 17, 2011 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has initiated discussions to implement the company's safety pre-matching locking device technology for blood transfusion vials with Israel's national Emergency Medical Services Provider who oversea the entire Nation's Blood Banks.
Discussions are with Israel's Magen David Adom, or Red Shield of David. This organization is the international equivalent of the Red Cross or Red Crescent and Magen David Adom are responsible for and overlook all of the national blood banks that provide blood to Israeli hospitals and other Medical Clinics in Israel.
Discussions are to focus on implementing Medisafe 1 Technology's patented pre-matching safety locking device on blood bags and vials. Using the technology, a barcode reader would need to electronically confirm that a particular patient was being administered the appropriate and correct blood type prior to the release of the blood from the vial.
"Improper infusion of blood caused by human error is an avoidable cause of death," said, Jacob Elhadad, CEO of Medisafe 1 Technologies. "Applying the concepts behind our patented pre-matching safety locking device technology to infusion bags, and blood vials can contribute to a reduction in the number of preventable deaths in hospitals."
"We are hopeful that the future implementation of the technology in Israel Blood Banks if approved can lead to its implementation in other countries. We have similarly initiated discussions with blood banks in the U nited States."
Medisafe 1 Technologies has already developed its locking device technology for syringes in hospitals. It is estimated that the application of the technology for infusion bags will be ready for demonstration within three months time.
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact: Jacob Elhadad CEO +972-524440000 [email protected]
SOURCE Medisafe 1 Technologies Corp.